GreenBone Ortho, a Genova-based biotech company focused on bone regeneration solutions, has launched an ambitious scientific experiment aboard the International Space Station to validate its innovative b.Bone biomimetic bone substitute. The company’s research payload traveled to the ISS aboard SpaceX CRS-34 on May 15-16, 2026, marking a significant milestone in the clinical development of regenerative medicine technologies.
The experiment represents a collaborative effort between GreenBone Ortho, San Martino Hospital, and the University of Genova, with technical support from space specialists Kayser Space and Comat. By testing b.Bone in microgravity conditions, researchers aim to observe how human bone cells adhere, proliferate, and differentiate on the scaffold material without the influence of Earth’s gravitational pull. This controlled environment provides unique insights into cellular behavior that cannot be replicated in traditional laboratory settings.
Advancing Bone Regeneration Research
The microgravity testing environment offers distinctive advantages for understanding bone cell interactions with biomimetic materials. The experiment’s findings could provide critical data for optimizing b.Bone’s design and effectiveness, potentially accelerating its path toward broader clinical applications. Preliminary results are expected by the end of 2026, with the potential to inform next-generation treatments for patients suffering from bone defects and degenerative conditions.
Saverio Gellini, CEO of GreenBone Ortho, expressed the company’s enthusiasm for the research opportunity: “Siamo estremamente entusiasti di questa opportunità unica di testare b.Bone in un ambiente così sfidante come la microgravità. I risultati di questo esperimento potrebbero rivoluzionare il trattamento dell’osteoporosi e offrire soluzioni concrete per la perdita di massa ossea che colpisce tante persone anziane ed in particolare le donne.”
Growth Stage Investment in Healthcare Innovation
The company has secured €10 million in total funding to support research and development of the b.Bone biomimetic bone substitute and this space-based validation experiment. This investment reflects growing confidence in GreenBone Ortho’s approach to addressing significant unmet needs in orthopedic and regenerative medicine, particularly for aging populations affected by bone loss conditions.
The research focuses on osteoporosis and bone defects that disproportionately impact elderly patients and women, highlighting the clinical relevance of the work. By validating b.Bone’s performance in an extreme environment like space, GreenBone Ortho aims to establish robust evidence for its efficacy in terrestrial medical applications.
European Innovation in Space-Based Research
GreenBone Ortho’s ISS experiment reflects a broader trend of European biotech companies leveraging space-based research platforms to advance healthcare innovations. As the European startup ecosystem continues to mature, more companies are recognizing the value of microgravity environments for validating novel medical technologies. This collaboration between Italian research institutions, private enterprise, and international space partners demonstrates the interconnected nature of Europe’s innovation landscape and the strategic importance of space-based research in developing next-generation medical solutions.